Mouse models of bleomycin-induced pulmonary fibrosis

Current Protocols in Pharmacology

Volumn , Issue SUPPL. 40, 2008, Pages

  Walters, Dianne M ^a   Kleeberger, Steven R ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Animal models; Aspiration; Bleomycin; Mice; Pulmonary fibrosis

Indexed keywords

BLEOMYCIN; COLLAGEN;

DISEASE MODEL; DISEASE SEVERITY; DNA STRAND BREAKAGE; EXPERIMENTAL MOUSE; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; LUNG FIBROSIS; LUNG INJURY; LUNG TOXICITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AZO COMPOUNDS; BIOLOGICAL ASSAY; BLEOMYCIN; COLLAGEN; COLORING AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LUNG; MICE; PULMONARY FIBROSIS; RATS; SPECIMEN HANDLING;

EID: 57349113079     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph0546s40     Document Type: Review

References (26)

1. Ashcroft, T., Simpson, J.M., and Timbrell, V. 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41:467-470.
2. Baecher-Allan, C.M. and Barth, R.K. 1993. PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. Reg. Immunol. 5:207-217.
3. Bhattacharjee, A. and Bansal, M. 2005. Collagen structure: TheMadras triple helix and the current scenario. IUBMB Life 57:161-172.
4. Chaudhary, N.I., Schnapp, A., and Park, J.E. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care. Med. 173:769-776.
5. Cho, H.Y., Reddy, S.P., Yamamoto, M., and Kleeberger, S.R. 2004. The transcription factor NRF2 protects against pulmonary fibrosis. Faseb. J. 18:1258-1260.
6. Chung, M.P., Monick, M.M., Hamzeh, N.Y., Butler, N.S., Powers, L.S., and Hunninghake, G.W. 2003. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am. J. Respir. Cell Mol. Biol. 29:375-380.
7. Ekimoto, H., Takada, K., Ohnuki, T., Takahashi, K., Matsuda, A., Takita, T., and Umezawa, H. 1987. Different sensitivity to bleomycin-induced pulmonary fibrosis among various strains of mice. J. Clin. Biochem. Nutr. 2:25-31.
8. Foster, W.M., Walters, D.M., Longphre, M., Macri, K., and Miller, L.M. 2001. Methodology for the measurement of mucociliary function in the mouse by scintigraphy. J. Appl. Physiol. 90:1111-1117.
9. Garantziotis, S. and Schwartz, D.A. 2006. Hostenvironment interactions in pulmonary fibrosis. Semin. Respir. Crit. Care Med. 27:574-580.
10. Harrison, J.H. Jr. and Lazo, J.S. 1987. High dose continuous infusion of bleomycin in mice: A newmodel for drug-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 243:1185-1194.
11. Harrison, J.H. Jr. and Lazo, J.S. 1988. Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 247:1052-1058.
12. Haston, C.K., Amos, C.I., King, T.M., and Travis, E.L. 1996. Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res. 56:2596-2601.
13. Iyer, S.N., Margolin, S.B., Hyde, D.M., and Giri, S.N. 1998. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp. Lung Res. 24:119-132.
14. Iyer, S.N., Hyde, D.M., and Giri, S.N. 2000. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 24:477-491.
15. Khalil, N., Churg, A., Muller, N., and O'Connor, R. 2007. Environmental, inhaled and ingested causes of pulmonary fibrosis. Toxicol. Pathol. 35:86-96.
16. Kinnula, V.L., Fattman, C.L., Tan, R.J., and Oury, T.D. 2005. Oxidative stress in pulmonary fibrosis: A possible role for redox modulatory therapy. Am. J. Respir. Crit. Care Med. 172:417-422.
17. Lawson, W.E., Polosukhin, V.V., Stathopoulos, G.T., Zoia, O., Han, W., Lane, K.B., Li, B., Donnelly, E.F., Holburn, G.E., Lewis, K.G., Collins, R.D., Hull, W.M., Glasser, S.W., Whitsett, J.A., and Blackwell, T.S. 2005. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am. J. Pathol. 167:1267-1277.
18. McConnell, E.E. and Davis, J.M. 2002. Quantification of fibrosis in the lungs of rats using a morphometric method. Inhal. Toxicol. 14:263-272.
19. Ogami, A., Morimoto, Y., Yamato, H., Oyabu, T., Kajiwara, T., and Tanaka, I. 2004. Patterns of histopathological change determined by the point counting method and its application for the hazard assessment of respirable dust. Inhal. Toxicol. 16:793-800.
20. Schrier, D.J., Kunkel, R.G., and Phan, S.H. 1983. The role of strain variation in murine bleomycininduced pulmonary fibrosis. Am. Rev. Respir. Dis. 127:63-66.
21. Serrano-Mollar, A., Closa, D., Prats, N., Blesa, S., Martinez-Losa, M., Cortijo, J., Estrela, J.M., Morcillo, E.J., and Bulbena,O. 2003. In vivo antioxidant treatment protects against bleomycininduced lung damage in rats. Br. J. Pharmacol. 138:1037-1048.
22. Sweat, F., Puchtler, H., and Rosenthal, S.I. 1964. Sirius Red F3ba as a Stain forConnectiveTissue. Arch. Pathol. 78:69-72.
23. Tullberg-Reinert, H. and Jundt, G. 1999. In situ measurement of collagen synthesis by human bone cells with a Sirius Red-based colorimetric microassay: Effects of transforming growth factor beta2 and ascorbic acid 2-phosphate. Histochem. Cell Biol. 112:271-276.
24. Umezawa, H., Maeda, K., Takeuchi, T., and Okami, Y. 1966. New antibiotics, bleomycin A and B. J. Antibiot. (Tokyo) 19:200-209.
25. Weiss, R.B. 1992. Hypersensitivity reactions. Semin. Oncol. 19:458-477.
26. Woessner, J.F. Jr. 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93:440-447.